Regenxbio Inc (RGNX, Financial) is set to release its Q3 2024 earnings on Nov 6, 2024. The consensus estimate for Q3 2024 revenue is $23.59 million, and the earnings are expected to come in at -$1.12 per share. The full year 2024's revenue is expected to be $95.41 million and the earnings are expected to be -$4.53 per share. More detailed estimate data can be found on the Forecast page.
Regenxbio Inc (RGNX, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Regenxbio Inc (RGNX) have declined from $95.89 million to $95.41 million for the full year 2024. For 2025, estimates have increased from $294.2 million to $302.48 million. Earnings estimates for 2024 have declined from -$4.50 per share to -$4.53 per share, while for 2025, estimates have improved from -$1.36 per share to -$0.80 per share.
Regenxbio Inc (RGNX, Financial) Reported History
In the previous quarter of June 30, 2024, Regenxbio Inc's (RGNX) actual revenue was $22.3 million, which missed analysts' revenue expectations of $22.973 million by -2.95%. Regenxbio Inc's (RGNX) actual earnings were -$1.05 per share, which beat analysts' earnings expectations of -$1.289 per share by 18.54%. After releasing the results, Regenxbio Inc (RGNX) was down by -2.03% in one day.
Regenxbio Inc (RGNX, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 13 analysts, the average target price for Regenxbio Inc (RGNX) is $36.54 with a high estimate of $52 and a low estimate of $18. The average target implies an upside of 317.11% from the current price of $8.76.
Based on GuruFocus estimates, the estimated GF Value for Regenxbio Inc (RGNX, Financial) in one year is $40.74, suggesting an upside of 365.07% from the current price of $8.76.
Based on the consensus recommendation from 13 brokerage firms, Regenxbio Inc's (RGNX, Financial) average brokerage recommendation is currently 1.8, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
